Fresenius SE & Co. KGaA

XETRA FRE.DE

Fresenius SE & Co. KGaA Debt to Equity Ratio for the year ending December 31, 2023: 0.83

Fresenius SE & Co. KGaA Debt to Equity Ratio is 0.83 for the year ending December 31, 2023, a -38.73% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Fresenius SE & Co. KGaA Debt to Equity Ratio for the year ending December 31, 2022 was 1.36, a -4.86% change year over year.
  • Fresenius SE & Co. KGaA Debt to Equity Ratio for the year ending December 31, 2021 was 1.43, a -6.51% change year over year.
  • Fresenius SE & Co. KGaA Debt to Equity Ratio for the year ending December 31, 2020 was 1.53, a -5.89% change year over year.
  • Fresenius SE & Co. KGaA Debt to Equity Ratio for the year ending December 31, 2019 was 1.62, a 30.85% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
XETRA: FRE.DE

Fresenius SE & Co. KGaA

CEO Mr. Michael Sen
IPO Date Nov. 9, 1998
Location Germany
Headquarters Else-Kroener-Strasse 1
Employees 177,091
Sector Health Care
Industries
Description

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Similar companies

MRK.DE

MERCK Kommanditgesellschaft auf Aktien

USD 145.16

0.75%

HEI.DE

HeidelbergCement AG

USD 128.16

1.59%

FME.DE

Fresenius Medical Care AG & Co. KGaA

USD 44.66

0.37%

BEI.DE

Beiersdorf Aktiengesellschaft

USD 127.49

-1.31%

StockViz Staff

January 15, 2025

Any question? Send us an email